PURPOSE: To determine the impact of stereotactic radiosurgery (SRS) on the clinical course, hormonal status, and follow-up CT/MRI scan of @entity4611 . METHODS AND MATERIALS: From July 1988 to March 1996, 24 @entity4611 had been treated using 6 MV linear accelerator based SRS. They consisted of 11 (45.8%) @entity2013 , 2 (8.3%) @entity2124 ( @entity2124 )-secreting @entity5 , 1 (4.2%) @entity699 , 8 (33.3%) nonsecreting (nonfunctioning: NF) @entity5 , and 2 (8.3%) mixed prolactin- @entity2124 (PRL-GH)-secreting @entity5 (M:F = 12:12; aged 21-61 years). Postoperative irradiation was performed in all cases except for the instance of @entity699 . The prescribed dose to @entity5 center varied from 10 to 27 Gy (mean 21.1 Gy) using a collimator size of 0.5 to 2.5 cm. The follow-up duration ranged from 13 to 89 months (mean 49.2 months). Results from these @entity1 were compared to our results using conventional radiation. RESULTS: Visual acuity and field defect were improved or became normal in 19 (79.2%) cases. Four (16.7%) remained unchanged after the treatment. One (4.1%) progressed 6 years after SRS and subsequently had repeat surgery with conventional boost irradiation. Of the 13 (46.4%) @entity2013 , including two mixed @entity5 , 11 (84.1%) revealed normal hormonal levels within 1 year after SRS. In contrast, it took 2 years to become normal after conventional radiation therapy. In four @entity2124 -secreting @entity5 including two mixed @entity5 , SRS and conventional methods showed similar responses. On follow-up imagings of the 21 @entity1 , the mass was completely resolved in 4 (16.7%), including 3 PRLs and one NF, decreased in 11 (45.8%), and unchanged in 5 (16.7%) with central @entity39 or cysts. One (4.2%) progressed and was reoperated 6 years after treatment. The complications related to SRS were comparable to those from conventional method. CONCLUSION: Radiosurgery can be used effectively in @entity1 with @entity977 . In this study, a more rapid hormonal and clinical response was achieved with radiosurgery than with conventional pituitary irradiation treatment.

Clinical results of 24 XXXX with linac-based stereotactic radiosurgery.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2013 :: ('MESH:D015175', 'Disease') :: ['prolactinomas'] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'PRL-GH secreting tumors', 'tumors'] @entity699 :: ('MESH:D003480', 'Disease') :: ["Cushing's disease"] @entity4611 :: ('MESH:D010900', 'Disease') :: ['pituitary macroadenomas'] @entity2124 :: ('2688', 'Gene') :: ['GH', 'growth hormone'] @entity977 :: ('MESH:D010911', 'Disease') :: ['pituitary adenoma']
@entity4611 :: (MESH:D010900,Disease) :: ['pituitary macroadenomas']
